Mark is a seasoned biopharmaceutical executive and commercial leader with extensive experience in product marketing, commercial strategy, operations, management consulting, and market research. He currently serves as Head of Commercial at Verastem Oncology, leading the launch of avutometinib and defactinib for low-grade serous ovarian cancer. Previously, he led the Product Innovation and Monetization Practice at Real Chemistry and the Oncology and Specialty Business Unit at Kantar Health, overseeing product development, research, and commercialization initiatives.

Earlier in his career, Mark successfully launched Contrave at Orexigen Therapeutics and spent nearly two decades in roles of increasing responsibility at Merck & Co. He holds a BS in Exercise Science, an MS in Cardiac Rehabilitation from Slippery Rock University of Pennsylvania, and an MBA from the University of New Hampshire.

Jenny is a leading expert in federal health policy and strategy. She most recently led the development and implementation of legislative, regulatory, and political advocacy strategies as Executive Vice President of Policy, Research and Membership at PhRMA. She has previously held positions at The Lewin Group, Blue Cross Blue Shield Association, Blue Cross Blue Shield of Florida, New York Hospital-Cornell Medical Center, and the State of New York.

Jenny earned her AB in Social Studies from Harvard University and her MBA from Harvard Business School.

Laureenisa corporate communications leader with more than 25 years of strategic communications experience in the health sector. She is currently president at Outcomes Communication Group, a consultancy with expertise in crisis management, thought leadership, investor communication, and employee engagement.Laureenpreviously served as CCO for Baxter International and served in a number of public affairs roles at Abbott Laboratories, where she also helped develop the company’s first-ever multi-national public affairs function.

She earned both her BA and MBA from Loyola University Chicago.

Donna is an award-winning, published patient advocate and social impact entrepreneur. A 27-year liver transplant recipient herself, she is the Founder, President and CEO of the Global Liver Institute, the only patient-driven liver health nonprofit operating across the U.S., EU, and UK. Donna is also Founder of CryerHealth, a consulting firm advising organizations from across the healthcare ecosystem on patient engagement in health information technology, drug discovery and clinical decision making. She is also a frequent keynote speaker on these topics.

Donna previously held roles at the United Network for Organ Sharing and the People-Centered Research Foundation and holds an AB in Government from Harvard University and her JD from Georgetown University Law Center.

Mike is an executive leader with more than thirty years of life science experience, spanning leadership roles in manufacturing, marketing, and research. Most recently, Mike was Global Head of Cerner Enviza (formerly Kantar Health), where he led a global team of researchers, scientists, and consultants delivering real-world evidence, commercial research, data analytics, and consulting services across the life sciences industry. He previously served as President and COO of Kantar Health, held roles at TargetRx, Merck, and Johnson & Johnson.

Mike earned his BS in Packaging Technology from the Rochester Institute of Technology and his MBA from Saint Joseph’s University.

David is a communications executive with extensive experience developing and implementing corporate communications strategies, including reputation management, executive visibility, public affairs, and government relations. He is currently Executive Vice President and Chief Global Communications and Public Affairs Officer at U.S. Bank and served as Chief Communications Officer at CVS Health during their strategic rebranding and removal of tobacco products from their stores.

David was formerly a Senior Advisor at Reservoir Communications Group and previously led communications at Wellpoint, Freddie Mac, Riggs National Bank, and Barnett Bank. He holds a BA in Journalism from the University of Delaware.

Orriel is an attorney and health law and financing policy expert. She currently serves as the Head of Health Equity and Policy at Morgan Health, JPMorganChase. Orriel previously served as health counsel to the U.S. House of Representatives Committee on Ways and Means and has held positions at the Center for Medicare and Medicaid Services and the District of Columbia Department of Health Care Finance.

Orriel holds a BS in Biology with minors in Chemistry, Spanish and Classics from Howard University and earned her MPH from Tulane University and her JD from George Washington University.

Paul is a biopharmaceutical executive with more than 35 years of industry experience, across multiple therapeutic areas. Most recently, he was President, CEO and Board Member of Helsinn Therapeutics, leading the company’s oncology and rare disease work in the U.S., and previously led the U.S. oncology and hematology branded business at Teva Pharmaceuticals. Paul has previously worked at IntraBiotics and Aventis Pharmaceuticals and predecessor companies, e.g. Hoechst Marion Roussel.

He holds a Bachelor’s degree in Psychology, with minors in Chemistry and Biology, from the University of Missouri–Columbia, and earned his MBA from St. Ambrose University.